Translate Bio, Inc. Stock News

LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medici

-- MRT5005 is the first clinical-stage mRNA therapeutic with nebulized delivery to the lung and first to be administered in multiple doses for the treatment of a chronic genetic disease -- -- Complete

Big drugmakers could be attracted to these smaller players with promising pipelines.

TBIO is a leader in mRNA therapeutics. Its cystic fibrosis program has interim data from a phase 1 study.

We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.

LEXINGTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medici

In the race to develop a coronavirus vaccine, Pfizer and its partner BioNTech have a lead, closely followed by Moderna. However, four other biotechs, NVAX, TBIO, INO and VXRT, still hold potential to

Great efficacy results for mRNA COVID-19 vaccines so far could bode well for these three stocks.

-- Advances Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis ( CF ) with resumption of COVID-impacted enrollment and dosing -- -- Presented promising preclinical data at NACFC